Sinopharm Accord released its performance for the first half of the year, with a net profit attributable to the parent company of 666 million yuan, a year-on-year decrease of 10.43%

According to the Zhitong Finance APP, Sinopharm Accord (000028.SZ) released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 36.797 billion yuan, a year-on-year decrease of 2.62%. The net profit attributable to shareholders of the listed company was 666 million yuan, a year-on-year decrease of 10.43%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 643 million yuan, a year-on-year decrease of 9.63%. The basic earnings per share were 1.2 yuan